Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) announced positive additional data from the phase III (POISE) study on obeticholic acid (OCA) being developed for the treatment of primary biliary cirrhosis (PBC). Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) shares after opening at $255.01 moved to $259.27 on last trade day and at the end of the day closed at $248.97. Company price to sales ratio in past twelve months was calculated as 3130.80 and price to cash ratio as 34.57. Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) showed a negative weekly performance of -14.52%.
On April 14, 2014, Retrophin, Inc. (NASDAQ:RTRX) issued a press release updating earnings guidance for 2014 and 2015 and providing an update on the development of certain of the Registrant’s product candidates Retrophin Inc. (NASDAQ:RTRX) shares fell -10.84% in last trading session and ended the day on $11.60. RTRX return on assets is -707.30%. Retrophin Inc. (NASDAQ:RTRX) yearly performance is 78.46%.
KYTHERA Biopharmaceuticals (NASDAQ:KYTH) CEO Keith Leonard unloaded 13,260 shares of KYTHERA Biopharmaceuticals stock on the open market in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $39.08, for a total value of $518,200.80. Kythera Biopharmaceuticals Inc. (NASDAQ:KYTH) shares moved up 9.94% in last trading session and was closed at $35.82, while trading in range of $31.46 – $36.05. Kythera Biopharmaceuticals Inc. (NASDAQ:KYTH) year to date (YTD) performance is -4.10%.
On March 27, 2014, the Compensation Committee of the Board of Directors of Auspex Pharmaceuticals, Inc. (NASDAQ:ASPX) approved discretionary cash bonuses for certain of the Company’s named executive officers and the Company’s principal financial officer. Auspex Pharmaceuticals Inc. (NASDAQ:ASPX) weekly performance is -28.54%. On last trading day company shares ended up $21.46. Auspex Pharmaceuticals Inc. (NASDAQ:ASPX) distance from 50-day simple moving average (SMA50) is -22.05%. Analysts mean target price for the company is $38.50.